A LinkedIn post from Forge Biologics centers on discussions at the Alliance for Regenerative Medicine’s CGMed26 meeting about key positive trends in Europe’s cell and gene therapy market amid intensifying global competition and evolving regulation. The post notes that company representative Taleen Barsoumian described how Forge works with European adeno-associated virus (AAV) therapy developers across the development cycle.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, this support ranges from early research-grade material manufacturing to global regulatory guidance, including experience with successful clinical trial applications in the U.K. and under the European Union’s new Clinical Trials Regulation. For investors, the emphasis on European capabilities and regulatory know-how suggests Forge may be positioning itself as a specialized manufacturing and development partner in a growing regional market.
If sustained, this focus could help the company deepen its customer base among emerging and established gene therapy sponsors seeking to navigate complex European frameworks. It may also reinforce Forge’s competitive differentiation in the contract development and manufacturing organization segment, potentially supporting future revenue visibility tied to clinical pipeline activity in Europe.